$\require{mediawiki-texvc}$

연합인증

연합인증 가입 기관의 연구자들은 소속기관의 인증정보(ID와 암호)를 이용해 다른 대학, 연구기관, 서비스 공급자의 다양한 온라인 자원과 연구 데이터를 이용할 수 있습니다.

이는 여행자가 자국에서 발행 받은 여권으로 세계 각국을 자유롭게 여행할 수 있는 것과 같습니다.

연합인증으로 이용이 가능한 서비스는 NTIS, DataON, Edison, Kafe, Webinar 등이 있습니다.

한번의 인증절차만으로 연합인증 가입 서비스에 추가 로그인 없이 이용이 가능합니다.

다만, 연합인증을 위해서는 최초 1회만 인증 절차가 필요합니다. (회원이 아닐 경우 회원 가입이 필요합니다.)

연합인증 절차는 다음과 같습니다.

최초이용시에는
ScienceON에 로그인 → 연합인증 서비스 접속 → 로그인 (본인 확인 또는 회원가입) → 서비스 이용

그 이후에는
ScienceON 로그인 → 연합인증 서비스 접속 → 서비스 이용

연합인증을 활용하시면 KISTI가 제공하는 다양한 서비스를 편리하게 이용하실 수 있습니다.

2'-O-acetamido modified monomers and oligomers 원문보기

IPC분류정보
국가/구분 United States(US) Patent 등록
국제특허분류(IPC7판)
  • C07H-021/02
출원번호 US-0378568 (1999-08-19)
발명자 / 주소
  • Manoharan Muthiah
  • Kawasaki Andrew M.
  • Cook Phillip Dan
  • Fraser Allister S.
  • Prakash Thazha P.
출원인 / 주소
  • Isis Pharmaceuticals, Inc.
대리인 / 주소
    Woodcock Washburn Kurtz Mackieicz & Norris LLP
인용정보 피인용 횟수 : 135  인용 특허 : 100

초록

Nucleosidic monomers and oligomeric compounds prepared therefrom are provided. Also provided is a novel method of deprotection of oligomeric compounds. Oligomeric compounds having at least one 2'-O-acetamido modified nucleosidic monomer are expected to have increased nuclease resistance and binding

대표청구항

[ What is claimed is:] [1.] A compound having the formula: [ STR 7 ] wherein: Bx is an optionally protected heterocyclic base moiety;each T.sub.1 and T.sub.2 is, independently, OH, a protected hydroxyl;or one of T.sub.1 and T.sub.2 is OH or a protected hydroxyl and the other of T.sub.1 and T.sub.2 i

이 특허에 인용된 특허 (100)

  1. Buhr Chris A. ; Matteucci Mark, 2' Modified Oligonucleotides.
  2. Cook Phillip Dan ; Kawasaki Andrew Mamoru, 2'-modified oligonucleotides.
  3. Huynh Dinh Tam (Croissy/Seine FRX) Gouyette Catherine (Vanves FRX) Igolen Jean (Le Mesnil St. Denis FRX), 2,N6-disubstituted and 2,N6-trisubstituted adenosine-3′-phosphoramidites.
  4. Buhr Chris A. (Daly City CA) Matteucci Mark (Burlingame CA), 2\modified nucleoside and nucleotide compounds.
  5. Montgomery John A. (Birmingham AL) Secrist ; III John A. (Birmingham AL), 2′-deoxy-4′-thioribonucleosides and their antiviral activity.
  6. Usman Nassim (Boulder CO) Karpeisky Alexander (Boulder CO) Beigelman Leonid (Longmont CO) Modak Anil (Boulder CO), 2′deoxy-2′-alkylnucleotide containing nucleic acid.
  7. Cook P. Dan (Carlsbad CA) Acevedo Oscar L. (San Diego CA) Andrews Robert S. (San Juan Capistrano CA), 3-deazapurines.
  8. Cook Philip D. (Carlsbad CA) Sanghvi Yogesh S. (San Marcos CA), 4′-desmethyl nucleoside analog compounds.
  9. Cook Philip D. (Carlsbad CA) Delecki Daniel J. (Radnor PA) Guinosso Charles (Vista CA), Acyclic nucleoside analogs and oligonucleotide sequences containing them.
  10. Kempe Tomas, Anhydrous amine cleavage of oligonucleotides.
  11. Ecker David J. (Carlsbad CA), Antisense inhibitors of the human immunodeficiency virus.
  12. Ecker David J. (Carlsbad CA), Antisense inhibitors of the human immunodeficiency virus phosphorothioate oligonucleotides.
  13. Crooke Stanley T. (Carlsbad CA) Mirabelli Christopher K. (Encinitas CA) Ecker David J. (Carlsbad CA) Cowsert Lex M. (Carlsbad CA), Antisense oligonucleotide inhibition of papillomavirus.
  14. Monia Brett P. (Carlsbad CA) Freier Susan M. (San Diego CA) Ecker David J. (Leucadia CA), Antisense oligonucleotide inhibition of the RAS gene.
  15. Monia Brett P. (Carlsbad CA) Freier Susan M. (San Diego CA) Ecker David J. (Leucadia CA), Antisense oligonucleotide inhibition of the ras gene.
  16. Monia Brett P. (Carlsbad CA) Boggs Russell T. (Cardiff-by-the-Sea CA), Antisense oligonucleotide modulation of raf gene expression.
  17. Pagano Joseph S. (Chapel Hill NC) Traub Nancy R. (Raleigh NC) Lin Jung-Chung (Atlanta GA), Antisense oligonucleotides against Epstein-Barr virus.
  18. Switzer Christopher (Moreno Valley CA), Antisense oligonucleotides comprising 5-aminoalkyl pyrimidine nucleotides.
  19. Draper Kenneth G. (San Marcos CA) Ecker David J. (Carlsbad CA) Mirabelli Christopher K. (Encinitas CA) Crooke Stanley T. (Carlsbad CA), Antisense oligonucleotides for inhibiting herpesviruses.
  20. Lima Walter (San Diego CA) Monia Brett (Carlsbad CA) Freier Susan (San Diego CA) Ecker David (Leucadia CA), Antisense oligonucleotides to the RAS gene.
  21. Cook Philip D. (Carlsbad CA) Sanghvi Yogesh S. (Carlsbad CA), Backbone modified oligonucleotide analogs.
  22. Sanghvi Yogesh S. (Carlsbad CA) Cook Phillip D. (Carlsbad CA), Backbone modified oligonucleotide analogs and preparation thereof through reductive coupling.
  23. Cook Phillip D. (Carlsbad CA) Sanghvi Yogesh S. (San Marcos CA) Morvan Francois (Montpellier FRX), Backbone modified oligonucleotide analogs and solid phase synthesis thereof.
  24. Leumann Christian (Zurich CHX), Bicyclic nucleosides, oligonucleotides, process for their preparation and intermediates.
  25. Leumann Christian (Zurich CHX), Bicyclic nucleosides, oligonucleotides, process for their preparation and intermediates.
  26. Matteucci Mark D. (Burlingame CA) Cao Xiaodong (Carlsbad CA), Binding compentent oligomers containing unsaturated 3′,5′and 2′,5′linkages.
  27. Spielvogel Bernard F. (Raleigh NC) Sood Anup (Durham NC) Hall Iris H. (Chapel Hill NC) Ramsay Shaw Barbara (Durham NC), Boronated nucleoside, nucleotide and oligonucleotide compounds, compositions and methods for using same.
  28. Ravikumar Vasulinga (Carlsbad CA) Andrade Mark (Carlsbad CA) Mulvey Dennis (Conroe TX) Cole Douglas L. (San Diego CA), Carbocation scavenging during oligonucleotide synthesis.
  29. Altmann Karl-Heinz (Basel CHX) Imwinkelried Rene (Brig-Glis CHX) Eschenmoser Albert (Kusnacht CHX), Carbocyclic nucleosides containing bicyclic rings, oligonucleotides therefrom, process for their preparation, their use.
  30. Altmann Karl-Heinz (Basel CHX) Imwinkelried Rene (Brig-Glis CHX) Eschenmoser Albert (Kusnacht CHX), Carbocyclic nucleosides containing bicyclic rings, oligonucleotides therefrom, process for their preparation, their use.
  31. Rieder Klaus-Hartwig (Stuttgart DEX), Circuit arrangement for a clock generator.
  32. Bertsch-Frank Birgit (Rheinfelden DEX) Klasen Claas-Juergen (Freigericht DEX) Lieser Thomas (Hapau DEX) Mueller Klaus (Hasselroth DEX) Bewersdorf Martin (Gelnhausen DEX), Coated sodium percarbonate particles, a process for their production and detergent, cleaning and bleaching compositions.
  33. Cook Phillip D. (Carlsbad CA) Bruice Thomas (Carlsbad CA) Guinosso Charles J. (Carlsbad CA) Kawasaki Andrew M. (Oceanside CA), Compositions for inhibiting RNA activity.
  34. Cook Phillip D. (Carlsbad CA) Manoharan Muthiah (Carlsbad CA) Bruice Thomas (Carlsbad CA), Covalently cross-linked oligonucleotides.
  35. Cook Phillip D. (Carlsbad CA) Baschang Gerhard (Bettingen CHX), Cyclobutyl oligonucleotide surrogates.
  36. Baxter Anthony D. (Northwich GB2) Baylis Eric K. (Stockport GB2) Collingwood Stephen P. (Westhoughton GB2) Taylor Roger J. (Stretford GB2) De Mesmaeker Alain (Kanerkinden CHX) Schmit Chantal (Basel C, Dinucleoside phosphinates and their pharmaceutical compositions.
  37. Froehler Brian (Belmont CA) Matteucci Mark (Burlingame CA), Enhanced triple-helix and double-helix formation with oligomers containing modified purines.
  38. Cook Phillip D. (Vista CA) Monia Brett P. (Carlsbad CA), Gapped 2′modified oligonucleotides.
  39. Rogers Thomas E. (Manchester MO) Gray Steven H. (Ellisville MO) Devadas Balekudru (Chesterfield MO) Adams Steven P. (St. Charles MO), Improved probes using nucleosides containing 3-dezauracil analogs.
  40. Cowsert Lex M. (Carlsbad CA) Ecker David J. (Carlsbad CA), Inhibition of influenza viruses by antisense oligonucleotides.
  41. Ecker David J. (Leucadia CA) Wyatt Jacqueline R. (Carlsbad CA) Imbach Jean L. (Montpellier FRX), Inhibitors of human immunodeficiency virus.
  42. Benner Steven A. (Hadlaubstrasse 151 CH-8006 Zurich CHX), Method for incorporating into a DNA or RNA oligonucleotide using nucleotides bearing heterocyclic bases.
  43. Quach Loc (Columbia MD) Fan Lai-Duien G. (Palatine IL), Method of inhibiting scale deposits.
  44. Reddy Parameswara M. (Brea CA) Hanna Naeem B. (Fullerton CA), Methods and reagents for cleaving and deprotecting oligonucleotides.
  45. Reddy Parameswara M. (Brea CA) Hanna Naeem B. (Fullerton CA), Methods and reagents for cleaving and deprotecting oligonucleotides.
  46. Swaminathan Sundaramoorthi ; Matteucci Mark ; Pudlo Jeff ; Jones Robert J., Modified internucleoside linkages (II).
  47. Cook P. Dan (Carlsbad CA) Ramasamy Kanda S. (Laguna Hills CA) Manoharan Muthiah (Carlsbad CA), N-2 substituted purines.
  48. Ts\o Paul O. P. (2117 Folkstone Rd. Lutherville MD 21093) Miller Paul S. (225 Hopkins Rd. Baltimore MD 21212), Nonionic nucleic acid alkyl and aryl phosphonates and processes for manufacture and use thereof.
  49. Cook Philip D. (Carlsbad CA) Sanghvi Yogesh S. (San Marcos CA), Nuclease resistant, pyrimidine modified oligonucleotides that detect and modulate gene expression.
  50. Bischofberger Norbert W. (San Carlos CA) Matteucci Mark D. (Burlingame CA), Nucleic acid intercalating agents.
  51. Haralambidis Jim (Victoria AUX), Nucleoside derivatives.
  52. Caruthers Marvin H. (Boulder CO) Matteucci Mark D. (San Francisco CA), Nucleosides useful in the preparation of polynucleotides.
  53. Sanghvi Yogesh S. (Carlsbad CA) Cook Phillip D. (Carlsbad CA), Oligonucleoside linkages containing adjacent oxygen and nitrogen atoms.
  54. Hecht Sidney M. (Charlottesville VA), Oligonucleotide N-alkylphosphoramidates.
  55. Huie Edward M. (Wilmington DE) Trainor George L. (Wilmington DE), Oligonucleotide analogs with sulfamate linkages.
  56. Bennett C. Frank (Carlsbad CA) Mirabelli Christopher K. (Encinitas CA), Oligonucleotide modulation of cell adhesion.
  57. Bennett C. Frank (Carlsbad CA) Mirabelli Christopher K. (Encinitas CA), Oligonucleotide modulation of cell adhesion.
  58. Baracchini ; Jr. Edgardo (San Diego CA) Bennett Clarence F. (Carlsbad CA), Oligonucleotide modulation of multidrug resistance-associated protein.
  59. Draper Kenneth G. (Boulder CO) Crooke Stanley T. (Carlsbad CA) Mirabelli Christopher K. (Encinitas CA) Ecker David J. (Leucadia CA) Hanecak Ronnie C. (San Clemente CA) Anderson Kevin P. (Carlsbad CA), Oligonucleotide therapies for modulating the effects of herpes viruses.
  60. Maag Hans (Menlo Park CA) Rose Samuel J. (Mountain View CA) Schmidt Beat (Baltschieder CHX), Oligonucleotides containing 4′-substituted nucleotides.
  61. Gmeiner William H. (Omaha NE) Iversen Patrick L. (Omaha NE), Oligonucleotides containing 5-fluorouracil.
  62. Froehler Brian (Belmont CA) Jones Robert J. (Daly City CA), Oligonucleotides containing 5-propynyl pyrimidines.
  63. Cook Phillip D. (San Marcos CA) Ramasamy Kanda S. (Laguna Hills CA) Manoharan Muthiah (Carlsbad CA), Oligonucleotides containing N-2 substituted purines.
  64. Cook Phillip D. (San Marcos CA) Hoke Glenn (Mt. Airy MD), Oligonucleotides for modulating hepatitis C virus having phosphorothioate linkages of high chiral purity.
  65. Anderson Kevin (Carlsbad CA) Draper Kenneth (Boulder CO) Baker Brenda (Encinitas CA), Oligonucleotides for modulating the effects of cytomegalovirus infections.
  66. Anderson Kevin P. (Carlsbad CA) Draper Kenneth G. (Richmond OH), Oligonucleotides for modulating the effects of cytomegalovirus infections.
  67. Cook Phillip D. (San Marcos CA) Hoke Glenn (Mt. Airy MD), Oligonucleotides having phosphorothioate linkages of high chiral purity.
  68. Smith Lloyd M. (South Pasadena CA) Fung Steven (Palo Alto CA) Kaiser ; Jr. Robert J. (Glendale CA), Oligonucleotides possessing a primary amino group in the terminal nucleotide.
  69. Lebleu Bernard (Montpellier FRX) Bayard Bernard (Castelnau Le Lez FRX), Oligonucleotides with modified phosphate and modified carbohydrate moieties at the respective chain termini.
  70. Urdea Michael S. (Alamo CA) Horn Thomas (Berkeley CA), Oligonucleotides with selectably cleavable and/or abasic sites.
  71. Spielvogel Bernard F. (Raleigh NC) Sood Anup (Durham NC) Hall Iris H. (Chapel Hill NC) Shaw Barbara R. (Durham NC), Oligoribonucleoside and oligodeoxyribonucleoside boranophosphates.
  72. Barascut Jean-Louis (Combaillaux FRX) Imbach Jean-Louis (Montpellier FRX), Oligothionucleotides.
  73. Caruthers Marvin H. (Boulder CO) Beaucage Serge L. (Boulder CO), Phosphoramidite compounds and processes.
  74. Misiura Konrad (Lodz PLX) Gait Michael (Cambridge GB3), Phosphoramidite derivatives, their preparation and the use thereof in the incorporation of reporter groups on synthetic.
  75. Caruthers Marvin H. (Boulder CO) Beaucage Serge L. (Mountain View CA), Phosphoramidite nucleoside compounds.
  76. Cook Philip D. (Carlsbad CA) Guinosso Charles J. (Carlsbad CA), Polyamine conjugated oligonucleotides.
  77. Cook Philip D. (Carlsbad CA) Guinosso Charles J. (Carlsbad CA), Polyamine conjugated oligonucleotides.
  78. Caruthers Marvin H. (Boulder CO) Marshall William S. (Boulder CO), Polynucleotide phosphorodithioates.
  79. Urdea Michael S. (Alamo CA) Horn Thomas (Berkeley CA), Polynucleotide reagents containing modified deoxyribose moieties, and associated methods of synthesis and use.
  80. Caruthers Marvin H. (Boulder CO) Beaucage Serge L. (Mountain View CA), Process for oligonucleo tide synthesis using phosphormidite intermediates.
  81. Caruthers Marvin H. (Boulder CO) Matteucci Mark D. (Boulder CO), Process for preparing polynucleotides.
  82. Caruthers Marvin H. (Boulder CO) Matteucci Mark D. (Boulder CO), Process for preparing polynucleotides.
  83. McGee Daniel P. C. (Carlsbad CA), Process for the preparation of 2′-O-alkyl guanosine and related compounds.
  84. McGee Daniel Peter Claude (Boulder CO), Process for the preparation of 2′-O-alkyl purine phosphoramidites.
  85. Kster Hubert (Concord MA) Sinha Nanda D. (San Rafael CA), Process for the preparation of oligonucleotides.
  86. Kster Hubert (Hamburg DEX) Sinha Nanda D. (Bundu Dt. Ranchi INX), Process for the preparation of oligonucleotides.
  87. Weis Alexander L. (Berwyn PA) Saha Ashis K. (Frazer PA) Hausheer Frederick H. (San Antonio TX), Process of linking nucleosides with a siloxane bridge.
  88. Hawkins Mary E. (Potomac MD) Pfleiderer Wolfgang (Konstanz MD DEX) Davis Michael D. (Rockville MD) Balis Frank (Bethesda MD), Pteridine nucleotide analogs as fluorescent DNA probes.
  89. Matteucci Mark D. (Burlingame CA) Jones Robert J. (Millbrae CA) Lin Kuei-Ying (Fremont CA), Pyrimidine derivatives for labeled binding partners.
  90. Acevedo Oscar L. (San Diego CA) Hebert Normand (San Marcos CA), Pyrrolidine-containing monomers and oligomers.
  91. Kempe Tomas (Bowie MD), Recovery of oligonucleotides by gas phase cleavage.
  92. Yau Eric K. (Kirkland WA), S-(2,4-dichlorobenzyl)-b 상세보기
  • Agrawal, Sudhir; Tang, Jinyan, Site-specific functionalization of oligodeoxynucleotides for non-radioactive labelling.
  • Van Ness Jeffrey (Bothell WA) Petrie Charles R. (Woodinville WA) Tabone John C. (Bothell WA) Vermeulen Nicolaas M. J. (Woodinville WA), Solid supports for nucleic acid hybridization assays.
  • Cook Phillip Dan (Carlsbad CA) Manoharan Muthiah (Carlsbad CA) Ramasamy Kanda S. (Laguna Hills CA), Substituted purines and oligonucleotide cross-linking.
  • Cook Phillip Dan (Carlsbad CA) Kawasaki Andrew Mamoro (Oceanside CA), Sugar modified oligonucleotides that detect and modulate gene expression.
  • Cook P. Dan ; Acevedo Oscar L. ; Andrews Robert S., Synthesis of 3-deazapurines.
  • Ravikumar Vasulinga (Carlsbad CA) Cole Douglas L. (San Diego CA), Synthesis of oligonucleotides.
  • Cook Phillip D. (Carlsbad CA) Manoharan Muthiah (Carlsbad CA), Thiol-derivatized nucleosides.
  • Summerton, James E.; Weller, Dwight D., Uncharged morpholino-based polymers having achiral intersubunit linkages.
  • 이 특허를 인용한 특허 (135)

    1. Prakash, Thazha P.; Baker, Brenda F.; Eldrup, Anne B.; Manoharan, Muthiah; Bhat, Balkrishen; Griffey, Richard; Swayze, Eric E.; Crooke, Stanley T., 2′-Fluoro substituted oligomeric compounds and compositions for use in gene modulations.
    2. Sekine, Mitsuo; Yamada, Takeshi; Saneyoshi, Hisao; Seio, Kohji, 2′-hydroxyl group-modified ribonucleoside derivatives.
    3. Gelfand, David H.; Bauer, Keith A.; Gupta, Amar P.; Bodepudi, Veeraiah; Niemiec, John, 2′-terminator related pyrophosphorolysis activated polymerization.
    4. Collard, Joseph; Khorkova Sherman, Olga; De Leon, Belinda, Antagonat compositions and methods of use.
    5. Shimizu, Mamoru; Wada, Takeshi, Asymmetric auxiliary group.
    6. Shimizu, Mamoru; Wada, Takeshi, Asymmetric auxiliary group.
    7. Crooke, Stanley T., Chimeric oligomeric compounds and their use in gene modulation.
    8. Butler, David; Iwamoto, Naoki; Meena; Svrzikapa, Nenad; Verdine, Gregory L.; Zlatev, Ivan, Chiral control.
    9. Butler, David; Iwamoto, Naoki; Meena; Svrzikapa, Nenad; Verdine, Gregory L.; Zlatev, Ivan, Chiral control.
    10. Meena; Butler, David; Iwamoto, Naoki; Svrzikapa, Nenad; Verdine, Gregory L.; Zlatev, Ivan, Chiral design.
    11. Gemba, Takefumi, Chiral nucleic acid adjuvant.
    12. Gemba, Takefumi; Nagata, Ryoichi; Torikai, Yusuke, Chiral nucleic acid adjuvant having antitumor effect and antitumor agent.
    13. Gemba, Takefumi; Nagata, Ryoichi; Shiga, Ikumi, Chiral nucleic acid adjuvant having immunity induction activity, and immunity induction activator.
    14. Krotz, Achim; Capaldi, Daniel C.; Gaus, Hans-Joachim Josef; Turney, Brett, Chloral-free DCA in oligonucleotide synthesis.
    15. Krotz,Achim; Capaldi,Daniel; Gaus,Hans; Turney,Brett, Chloral-free DCA in oligonucleotide synthesis.
    16. Dobie, Kenneth W.; Dean, Nicholas M.; Bennett, C. Frank, Compositions and their uses directed to HBXIP.
    17. Karras, James G.; Gregory, Susan; Crosby, Jeffrey R.; Guha, Mausumee; Tung, David; Freier, Susan M., Compositions and their uses directed to IL-4R alpha.
    18. Karras,James G.; Gregory,Susan; Freier,Susan M.; Gaarde,William A.; Guha,Mausumee, Compositions and their uses directed to IL-4R alpha.
    19. Freier, Susan M., Compositions and their uses directed to huntingtin.
    20. Freier, Susan M., Compositions and their uses directed to huntingtin.
    21. Freier, Susan M., Compositions and their uses directed to huntingtin.
    22. Hung, Gene; Leeds, Janet M.; Bennett, C. Frank; Freier, Susan M., Compositions and their uses directed to huntingtin.
    23. Allerson, Charles; Bhat, Balkrishen; Eldrup, Anne B.; Manoharan, Muthiah; Griffey, Richard H.; Baker, Brenda F.; Swayze, Eric E., Compositions comprising alternating 2′-modified nucleosides for use in gene modulation.
    24. Capaldi,Daniel C.; Gaus,Hans Joachim Josef; Rentel,Claus Andre Frank; Olsen,Philip Dmitri; Kurata,Christine C.; Song,Quanlai, Compounds and methods for the characterization of oligonucleotides.
    25. Bennett, C. Frank; McKay, Robert; Monia, Brett P.; Baker, Brenda F.; Sioufi, Namir, Conjugates for use in hepatocyte free uptake assays.
    26. Baker, Brenda F.; Kraynack, Bryan A., Double stranded constructs comprising one or more short strands hybridized to a longer strand.
    27. Yamada, Christina; Khvorova, Anastasia; Kaiser, Rob; Anderson, Emily; Leake, Devin, Duplex oligonucleotide complexes and methods for gene silencing by RNA interference.
    28. Khvorova, Anastasia; Leake, Devin; Robertson, Barbara; Vermeulen, Annaleen; Yamada, Christina, Duplex oligonucleotides with enhanced functionality in gene regulation.
    29. Wada, Takeshi; Shimizu, Mamoru, Method for the synthesis of phosphorus atom modified nucleic acids.
    30. Wada, Takeshi; Shimizu, Mamoru, Method for the synthesis of phosphorus atom modified nucleic acids.
    31. Verdine, Gregory L.; Meena; Iwamoto, Naoki; Butler, David Charles Donnell, Methods for the synthesis of functionalized nucleic acids.
    32. Prakash, Thazha P.; Manoharan, Muthiah, Methods of modulating pharmacokinetics of oligonucleotides.
    33. Leake, Devin; Reynolds, Angela R; Khvorova, Anastasia; Marshall, William, Modified polynucleotides for reducing off-target effects in RNA interference.
    34. Leake, Devin; Reynolds, Angela; Khvorova, Anastasia; Marshall, William; Linsley, Peter S., Modified polynucleotides for reducing off-target effects in RNA interference.
    35. Hung, Gene; Bennett, C. Frank; Freier, Susan M.; Kordasiewicz, Holly; Stanek, Lisa; Cleveland, Don W.; Cheng, Seng H.; Shihabuddin, Lamya, Modulation of huntingtin expression.
    36. Hung, Gene; Bennett, C. Frank; Freier, Susan M.; Kordasiewicz, Holly; Stanek, Lisa; Cleveland, Don W.; Cheng, Seng H.; Shihabuddin, Lamya, Modulation of huntingtin expression.
    37. Hung, Gene; Bennett, C. Frank; Freier, Susan M.; Kordasiewicz, Holly; Stanek, Lisa; Cleveland, Don W.; Cheng, Seng H.; Shihabuddin, Lamya, Modulation of huntingtin expression.
    38. Wahlestedt, Claes, Natural antisense and non-coding RNA transcripts as drug targets.
    39. Verdine, Gregory L.; ., Meena; Iwamoto, Naoki, Nucleic acid prodrugs and methods of use thereof.
    40. Esau, Christine; Swayze, Eric E.; Bhat, Balkrishen; Kinberger, Garth A., Oligomeric compounds and compositions for the use in modulation of microRNAs.
    41. Esau, Christine; Swayze, Eric E.; Bhat, Balkrishen; Kinberger, Garth A., Oligomeric compounds and compositions for the use in modulation of micrornas.
    42. Esau, Christine; Swayze, Eric E.; Bhat, Balkrishen; Kinberger, Garth A., Oligomeric compounds and compositions for the use in modulation of target nucleic acids.
    43. Bhat, Balkrishen; Dande, Prasad; Prakash, Thazha P.; Allerson, Charles; Swayze, Eric E.; Griffey, Richard H., Oligomeric compounds comprising 4′-thionucleosides for use in gene modulation.
    44. Oestergaard, Michael; Swayze, Eric E.; Seth, Punit P., Oligomeric compounds comprising alpha-beta-constrained nucleic acid.
    45. Moore,Max N.; Andrade,Mark; Carty,Recaldo; Scozzari,Anthony; Krotz,Achim, Oligonucleotide synthesis with alternative solvents.
    46. Crooke, Stanley T., Oligoribonucleotides and ribonucleases for cleaving RNA.
    47. Bhat, Balkrishen; Swayze, Eric E.; Prakash, Thazha P.; Allerson, Charles; Dande, Prasad; Griffey, Richard H., Positionally modified siRNA constructs.
    48. Song,Quanlai; Ross,Bruce S., Protection of nucleosides.
    49. Seth, Punit P.; Oestergaard, Michael; Swayze, Eric E., Selective antisense compounds and uses thereof.
    50. Corey, David R.; Hu, Jiaxin; Matsui, Masayuki, Selective inhibition of polyglutamine protein expression.
    51. Corey, David R.; Hu, Jiaxin; Matsui, Masayuki, Selective inhibition of polyglutamine protein expression.
    52. Collard, Joseph; Khorkova Sherman, Olga; Coito, Carlos, Treatment of 'IQ motif containing GTPase activating protein' (IQGAP) related diseases by inhibition of natural antisense transcript to IQGAP.
    53. Collard, Joseph; Khorkova Sherman, Olga, Treatment of ABCA1 gene related diseases by inhibition of a natural antisense transcript to ABCA1.
    54. Collard, Joseph; Khorkova Sherman, Olga, Treatment of Adiponectin (ADIPOQ) related diseases by inhibition of natural antisense transcript to an Adiponectin (ADIPOQ).
    55. Collard, Joseph; Khorkova Sherman, Olga, Treatment of Adiponectin related diseases by inhibition of natural antisense transcript to an Adiponectin.
    56. Collard, Joseph; Khorkova Sherman, Olga, Treatment of Frataxin (FXN) related diseases by inhibition of natural antisense transcript to FXN.
    57. Collard, Joseph; Khorkova Sherman, Olga, Treatment of LCAT gene related diseases by inhibition of a natural antisense transcript to LCAT.
    58. Collard, Joseph; Khorkova Sherman, Olga, Treatment of Methionine sulfoxide reductase a (MSRA) related diseases by inhibition of natural antisense transcript to MSRA.
    59. Collard, Joseph; Khorkova Sherman, Olga, Treatment of NANOG related diseases by inhibition of natural antisense transcript to NANOG.
    60. Collard, Joseph; Khorkova Sherman, Olga, Treatment of NANOG related diseases by inhibition of natural antisense transcript to NANOG.
    61. Collard, Joseph; Khorkova Sherman, Olga, Treatment of PAR4 related diseases by inhibition of natural antisense transcript to PAR4.
    62. Collard, Joseph; Khorkova Sherman, Olga, Treatment of PAR4 related diseases by inhibition of natural antisense transcript to PAR4.
    63. Collard, Joseph; Khorkova Sherman, Olga, Treatment of PAR4 related diseases by inhibition of natural antisense transcript to PAR4.
    64. Collard, Joseph; Khorkova Sherman, Olga, Treatment of Paraoxonase 1 (PON1) related diseases by inhibition of natural antisense transcript to PON1.
    65. Collard, Joseph; Khorkova Sherman, Olga, Treatment of RNASE H1 related diseases by inhibition of natural antisense transcript to RNASE H1.
    66. Collard, Joseph; Khorkova Sherman, Olga, Treatment of RNASE H1 related diseases by inhibition of natural antisense transcript to RNASE H1.
    67. Collard, Joseph; Khorkova Sherman, Olga, Treatment of adiponectin (ADIPOQ) related diseases by inhibition of natural antisense transcript to an adiponectin (ADIPOQ).
    68. Collard, Joseph; Khorkova Sherman, Olga; Coito, Carlos; Shen, Gang, Treatment of alpha-L-iduronidase (IDUA) related diseases by inhibition of natural antisense transcript to IDUA.
    69. Collard, Joseph; Khorkova Sherman, Olga; Coito, Carlos; Shen, Gang, Treatment of alpha-L-iduronidase (IDUA) related diseases by inhibition of natural antisense transcript to IDUA.
    70. Collard, Joseph; Khorkova Sherman, Olga, Treatment of antiviral gene related diseases by inhibition of natural antisense transcript to an antiviral gene.
    71. Collard, Joseph; Khorkova Sherman, Olga, Treatment of antiviral gene related diseases by inhibition of natural antisense transcript to an antiviral gene.
    72. Collard, Joseph; Khorkova Sherman, Olga, Treatment of antiviral gene related diseases by inhibition of natural antisense transcript to an antiviral gene.
    73. Collard, Joseph; Khorkova, Olga, Treatment of apolipoprotein-A1 related diseases by inhibition of natural antisense transcript to apolipoprotein-A1.
    74. Collard, Joseph; Khorkova Sherman, Olga, Treatment of atonal homolog 1 (ATOH1) related diseases by inhibition of natural antisense transcript to ATOH1.
    75. Collard, Joseph; Khorkova Sherman, Olga, Treatment of atonal homolog 1 (ATOH1) related diseases by inhibition of natural antisense transcript to ATOH1.
    76. Collard, Joseph; Khorkova Sherman, Olga, Treatment of atonal homolog 1 (ATOH1) related diseases by inhibition of natural antisense transcript to ATOH1.
    77. Collard, Joseph; Khorkova Sherman, Olga, Treatment of atonal homolog 1 (ATOH1) related diseases by inhibition of natural antisense transcript to ATOH1.
    78. Collard, Joseph; Khorkova Sherman, Olga; Coito, Carlos, Treatment of brain derived neurotrophic factor (BDNF) related diseases by inhibition of natural antisense transcript to BDNF.
    79. Collard, Joseph; Khorkova Sherman, Olga, Treatment of colony-stimulating factor 3 (CSF3) related diseases by inhibition of natural antisene transcript to CSF3.
    80. Collard, Joseph; Khorkova Sherman, Olga, Treatment of colony-stimulating factor 3 (CSF3) related diseases by inhibition of natural antisense transcript to CSF3.
    81. Collard, Joseph; Khorkova Sherman, Olga, Treatment of colony-stimulating factor 3 (CSF3) related diseases by inhibition of natural antisense transcript to CSF3.
    82. Collard, Joseph; Khorkova Sherman, Olga; Coito, Carlos, Treatment of delta-like 1 homolog (DLK1) related diseases by inhibition of natural antisense transcript to DLK1.
    83. Collard, Joseph; Khorkova Sherman, Olga; Coito, Carlos, Treatment of delta-like 1 homolog (DLK1) related diseases by inhibition of natural antisense transcript to DLK1.
    84. Collard, Joseph; Khorkova Sherman, Olga; Coito, Carlos, Treatment of discs large homolog (DLG) related diseases by inhibition of natural antisense transcript to DLG.
    85. Collard, Joseph; Khorkova Sherman, Olga; Coito, Carlos, Treatment of discs large homolog (DLG) related diseases by inhibition of natural antisense transcript to DLG.
    86. Collard, Joseph; Khorkova Sherman, Olga; Coito, Carlos, Treatment of discs large homolog (DLG) related diseases by inhibition of natural antisense transcript to DLG.
    87. Collard, Joseph; Khorkova Sherman, Olga, Treatment of down syndrome gene related diseases by inhibition of natural antisense transcript to a down syndrome gene.
    88. Collard, Joseph; Khorkova Sherman, Olga, Treatment of down syndrome gene related diseases by inhibition of natural antisense transcript to a down syndrome gene.
    89. Collard, Joseph; Khorkova Sherman, Olga, Treatment of dystrophin family related diseases by inhibition of natural antisense transcript to DMD family.
    90. Collard, Joseph; Khorkova Sherman, Olga, Treatment of dystrophin family related diseases by inhibition of natural antisense transcript to DMD family.
    91. Collard, Joseph; Khorkova Sherman, Olga, Treatment of erythropoietin (EPO) related diseases by inhibition of natural antisense transcript to EPO.
    92. Collard, Joseph; Sherman, Olga Khorkova, Treatment of erythropoietin (EPO) related diseases by inhibition of natural antisense transcript to EPO.
    93. Collard, Joseph; Khorkova Sherman, Olga, Treatment of fibroblast growth factor 21 (FGF21) related diseases by inhibition of natural antisense transcript to FGF21.
    94. Collard, Joseph; Khorkova Sherman, Olga, Treatment of fibroblast growth factor 21 (FGF21) related diseases by inhibition of natural antisense transcript to FGF21.
    95. Collard, Joseph; Khorkova Sherman, Olga; Coito, Carlos, Treatment of filaggrin (FLG) related diseases by modulation of FLG expression and activity.
    96. Collard, Joseph; Khorkova Sherman, Olga, Treatment of frataxin (FXN) related diseases by inhibition of natural antisense transcript to FXN.
    97. Collard, Joseph; Khorkova Sherman, Olga, Treatment of hepatocyte growth factor (HGF) related diseases by inhibition of natural antisense transcript to HGF.
    98. Collard, Joseph; Khorkova Sherman, Olga, Treatment of hepatocyte growth factor (HGF) related diseases by inhibition of natural antisense transcript to HGF.
    99. Collard, Joseph; Khorkova Sherman, Olga, Treatment of insulin gene (INS) related diseases by inhibition of natural antisense transcript to an insulin gene (INS).
    100. Collard, Joseph; Khorkova Sherman, Olga, Treatment of insulin receptor substrate 2 (IRS2) related diseases by inhibition of natural antisense transcript to IRS2 and transcription factor E3 (TFE3).
    101. Collard, Joseph; Khorkova Sherman, Olga, Treatment of interferon regulatory factor 8 (IRF8) related diseases by inhibition of natural antisense transcript to IRF8.
    102. Collard, Joseph; Sherman, Olga Khorkova, Treatment of interferon regulatory factor 8 (IRF8) related diseases by inhibition of natural antisense transcript to IRF8.
    103. Collard, Joseph; Khorkova Sherman, Olga, Treatment of membrane bound transcription factor peptidase, site 1 (MBTPS1) related diseases by inhibition of natural antisense transcript to MBTPS1.
    104. Collard, Joseph; Khorkova Sherman, Olga, Treatment of membrane bound transcription factor peptidase, site 1 (MBTPS1) related diseases by inhibition of natural antisense transcript to MBTPS1.
    105. Collard, Joseph; Khorkova Sherman, Olga, Treatment of methionine sulfoxide reductase a (MSRA) related diseases by inhibition of natural antisense transcript to MSRA.
    106. Collard, Joseph; Khorkova Sherman, Olga; Coito, Carlos, Treatment of nuclear factor (erythroid-derived 2)-like 2 (NRF2) related diseases by inhibition of natural antisense transcript to NRF2.
    107. Collard, Joseph; Khorkova Sherman, Olga, Treatment of nuclear respiratory factor 1 (NRF1) related diseases by inhibition of natural antisense transcript to NRF1.
    108. Collard, Joseph; Khorkova Sherman, Olga, Treatment of nuclear respiratory factor 1 (NRF1) related diseases by inhibition of natural antisense transcript to NRF1.
    109. Collard, Joseph; Khorkova Sherman, Olga, Treatment of pancreatic developmental gene related diseases by inhibition of natural antisense transcript to a pancreatic developmental gene.
    110. Collard, Joseph; Khorkova Sherman, Olga, Treatment of pancreatic developmental gene related diseases by inhibition of natural antisense transcript to a pancreatic developmental gene.
    111. Collard, Joseph; Khorkova Sherman, Olga, Treatment of paraoxonase 1 (PON1) related diseases by inhibition of natural antisense transcript to PON1.
    112. Collard, Joseph; Khorkova Sherman, Olga, Treatment of pyrroline-5-carboxylate reductase 1 (PYCR1) related disease by inhibition of natural antisense transcript to PYCR1.
    113. Collard, Joseph; Khorkova Sherman, Olga, Treatment of pyrroline-5-carboxylate reductase 1 (PYCR1) related diseases by inhibition of natural antisense transcript to PYCR1.
    114. Collard, Joseph; Khorkova Sherman, Olga, Treatment of pyrroline-5-carboxylate reductase 1 (PYCR1) related diseases by inhibition of natural antisense transcript to PYCR1.
    115. Collard, Joseph; Khorkova Sherman, Olga, Treatment of reprogramming factor related diseases by inhibition of natural antisense transcript to a reprogramming factor.
    116. Collard, Joseph; Khorkova Sherman, Olga, Treatment of reprogramming factor related diseases by inhibition of natural antisense transcript to a reprogramming factor.
    117. Collard, Joseph; Khorkova Sherman, Olga, Treatment of sex hormone binding globulin (SHBG) related diseases by inhibition of natural antisense transcript to SHBG.
    118. Collard, Joseph; Khorkova Sherman, Olga, Treatment of sialidase 4 (NEU4) related diseases by inhibition of natural antisense transcript to NEU4.
    119. Collard, Joseph; Khorkova Sherman, Olga; Coito, Carlos; De Leon, Belinda, Treatment of sirtuin (SIRT) related diseases by inhibition of natural antisense transcript to a sirtuin (SIRT).
    120. Collard, Joseph; Khorkova Sherman, Olga; De Leon, Belinda; Coito, Carlos; Hsiao, Jane H., Treatment of sodium channel, voltage-gated, alpha subunit (SCNA) related diseases by inhibition of natural antisense transcript to SCNA.
    121. Collard, Joseph; Khorkova Sherman, Olga, Treatment of transcription factor E3 (TFE3) and insulin receptor substrate 2 (IRS2) related diseases by inhibition of natural antisense transcript to TFE3.
    122. Collard, Joseph; Khorkova Sherman, Olga, Treatment of transcription factor E3 (TFE3) and insulin receptor substrate 2(IRS2) related diseases by inhibition of natural antisense transcript to TFE3.
    123. Collard, Joseph; Khorkova Sherman, Olga, Treatment of tristetraproline (TTP) related diseases by inhibition of natural antisense transcript to TTP.
    124. Collard, Joseph; Khorkova Sherman, Olga, Treatment of tristetraproline (TTP) related diseases by inhibition of natural antisense transcript to TTP.
    125. Collard, Joseph; Khorkova Sherman, Olga, Treatment of tumor necrosis factor receptor 2 (TNFR2) related diseases by inhibition of natural antisense transcript to TNFR2.
    126. Collard, Joseph; Khorkova Sherman, Olga, Treatment of tumor necrosis factor receptor 2 (TNFR2) related diseases by inhibition of natural antisense transcript to TNFR2.
    127. Collard, Joseph; Khorkova Sherman, Olga, Treatment of tumor protein 63 (p63) related diseases by inhibition of natural antisense transcript to p63.
    128. Collard, Joseph; Khorkova Sherman, Olga, Treatment of tumor protein 63 (p63) related diseases by inhibition of natural antisense transcript to p63.
    129. Collard, Joseph; Khorkova Sherman, Olga, Treatment of uncoupling protein 2 (UCP2) related diseases by inhibition of natural antisense transcript to UCP2.
    130. Collard, Joseph; Khorkova Sherman, Olga, Treatment of uncoupling protein 2 (UCP2) related diseases by inhibition of natural antisense transcript to UCP2.
    131. Collard, Joseph; Khorkova Sherman, Olga, Treatment of vascular endothelial growth factor (VEGF) related diseases by inhibition of natural antisense transcript to VEGF.
    132. Collard, Joseph; Sherman, Olga Khorkova, Treatment of vascular endothelial growth factor (VEGF) related diseases by inhibition of natural antisense transcript to VEGF.
    133. Collard, Joseph; Khorkova Sherman, Olga; Coito, Carlos, Treatment of ‘C terminus of HSP70-interacting protein’ (CHIP)related diseases by inhibition of natural antisense transcript to CHIP.
    134. Collard, Joseph; Khorkova Sherman, Olga; Coito, Carlos, Treatment of ‘C terminus of HSP7O-interacting protein’ (CHIP) related diseases by inhibition of natural antisense transcript to CHIP.
    135. Collard, Joseph; Khorkova Sherman, Olga; Coito, Carlos, Treatment of ‘IQ motif containing gtpase activating protein’ (IQGAP) related diseases by inhibition of natural antisense transcript to IQGAP.
    섹션별 컨텐츠 바로가기

    AI-Helper ※ AI-Helper는 오픈소스 모델을 사용합니다.

    AI-Helper 아이콘
    AI-Helper
    안녕하세요, AI-Helper입니다. 좌측 "선택된 텍스트"에서 텍스트를 선택하여 요약, 번역, 용어설명을 실행하세요.
    ※ AI-Helper는 부적절한 답변을 할 수 있습니다.

    선택된 텍스트

    맨위로